NO309266B1 - Fremgangsmåte for fremstilling av optisk anriket bupivacain - Google Patents
Fremgangsmåte for fremstilling av optisk anriket bupivacain Download PDFInfo
- Publication number
- NO309266B1 NO309266B1 NO971903A NO971903A NO309266B1 NO 309266 B1 NO309266 B1 NO 309266B1 NO 971903 A NO971903 A NO 971903A NO 971903 A NO971903 A NO 971903A NO 309266 B1 NO309266 B1 NO 309266B1
- Authority
- NO
- Norway
- Prior art keywords
- solvent
- bupivacaine
- water
- levobupivacaine
- optically enriched
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 20
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 title claims description 12
- 229960003150 bupivacaine Drugs 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title description 2
- 239000002904 solvent Substances 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 239000011975 tartaric acid Substances 0.000 claims abstract description 6
- 235000002906 tartaric acid Nutrition 0.000 claims abstract description 5
- 238000006243 chemical reaction Methods 0.000 claims abstract description 4
- 229960004288 levobupivacaine Drugs 0.000 claims description 7
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical group OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 claims description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
- 239000007787 solid Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229960001367 tartaric acid Drugs 0.000 description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960001050 bupivacaine hydrochloride Drugs 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- NTBIYBAYFBNTCD-UHFFFAOYSA-N dibenzoyl 2,3-dihydroxybutanedioate Chemical compound C=1C=CC=CC=1C(=O)OC(=O)C(O)C(O)C(=O)OC(=O)C1=CC=CC=C1 NTBIYBAYFBNTCD-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229960001464 levobupivacaine hydrochloride Drugs 0.000 description 1
- SIEYLFHKZGLBNX-NTISSMGPSA-N levobupivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCCC[NH+]1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C SIEYLFHKZGLBNX-NTISSMGPSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- JCQBWMAWTUBARI-UHFFFAOYSA-N tert-butyl 3-ethenylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(C=C)C1 JCQBWMAWTUBARI-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Compounds Of Unknown Constitution (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Epoxy Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9421476A GB9421476D0 (en) | 1994-10-25 | 1994-10-25 | Process and salt |
| GBGB9504926.8A GB9504926D0 (en) | 1995-03-10 | 1995-03-10 | Crystallisation |
| PCT/GB1995/002513 WO1996012699A1 (en) | 1994-10-25 | 1995-10-23 | Crystallisation of levobupivacaine and analogues thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO971903D0 NO971903D0 (no) | 1997-04-24 |
| NO971903L NO971903L (no) | 1997-04-24 |
| NO309266B1 true NO309266B1 (no) | 2001-01-08 |
Family
ID=26305863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO971903A NO309266B1 (no) | 1994-10-25 | 1997-04-24 | Fremgangsmåte for fremstilling av optisk anriket bupivacain |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5994548A (sv) |
| EP (1) | EP0788480B1 (sv) |
| JP (1) | JP3911545B2 (sv) |
| AT (1) | ATE245629T1 (sv) |
| AU (1) | AU698637B2 (sv) |
| CA (1) | CA2200355C (sv) |
| DE (1) | DE69531356T2 (sv) |
| DK (1) | DK0788480T3 (sv) |
| ES (1) | ES2202375T3 (sv) |
| FI (1) | FI117438B (sv) |
| HU (1) | HU227420B1 (sv) |
| MX (1) | MX9703024A (sv) |
| NO (1) | NO309266B1 (sv) |
| PL (1) | PL183210B1 (sv) |
| PT (1) | PT788480E (sv) |
| WO (1) | WO1996012699A1 (sv) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0002246A (pt) * | 2000-04-06 | 2003-04-15 | Cristalia Prod Quimicos Farm | Processo de obtenção dos enantiÈmeros da bupivacaìna racêmica, processo de obtenção de composições farmacêuticas a base de levobupivacaìna: composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis e utilização das composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis |
| BRPI0104491B8 (pt) * | 2001-10-10 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | n-(2,6-dimetilfenil)-1-propil-2-piperidinocarboxamida; processo de obtenção dos enantiômeros; mistura não racêmica dos anantiômeros e seu processo de obtenção e composição farmacêutica. |
| US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
| AU2003299659A1 (en) | 2002-12-13 | 2004-07-09 | Durect Corporation | Oral drug delivery system comprising high viscosity liquid carrier materials |
| US7094812B2 (en) * | 2003-04-24 | 2006-08-22 | Xerox Corporations | Colorant compositions |
| US6790267B1 (en) * | 2003-04-24 | 2004-09-14 | Xerox Corporation | Colorant compositions |
| NZ553369A (en) | 2004-09-17 | 2010-11-26 | Durect Corp | Sustained local anesthetic composition containing preferably a sugar ester such as saib |
| US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
| US20090187024A1 (en) * | 2006-04-25 | 2009-07-23 | Dishman Pharmaceuticals And Chemicals Ltd. | Ropivacaine hydrochloride anhydrate and the preparation thereof |
| PL2117521T3 (pl) | 2006-11-03 | 2012-11-30 | Durect Corp | Transdermalne systemy dostarczania zawierające bupiwakainę |
| EP2219622A1 (en) | 2007-12-06 | 2010-08-25 | Durect Corporation | Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition |
| ES2383714T3 (es) * | 2008-01-15 | 2012-06-25 | Pharmathen S.A. | Proceso para preparar un compuesto (S)-1-alquil-2',6'-pipecoloxilidídico |
| US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
| CN103073484B (zh) * | 2013-01-28 | 2014-10-22 | 山东诚创医药技术开发有限公司 | 一种甲哌卡因及其光学对映体的制备方法 |
| US9572885B2 (en) | 2013-03-15 | 2017-02-21 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
| RU2021114918A (ru) * | 2016-12-26 | 2021-07-09 | Целликс Био Прайвет Лимитед | Композиции и способы лечения хронической боли |
| CA3167217A1 (en) | 2020-01-13 | 2021-07-22 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE341404B (sv) * | 1967-05-18 | 1971-12-27 | Sterling Drug Inc | |
| US4695576A (en) * | 1984-07-09 | 1987-09-22 | Astra Lake Medel Aktiebolag | L-N-n-propylpipecolic acid-2,6-xylidide |
-
1995
- 1995-10-23 WO PCT/GB1995/002513 patent/WO1996012699A1/en active IP Right Grant
- 1995-10-23 HU HU9702372A patent/HU227420B1/hu unknown
- 1995-10-23 CA CA002200355A patent/CA2200355C/en not_active Expired - Lifetime
- 1995-10-23 US US08/849,418 patent/US5994548A/en not_active Expired - Lifetime
- 1995-10-23 PL PL95319829A patent/PL183210B1/pl unknown
- 1995-10-23 AU AU37048/95A patent/AU698637B2/en not_active Expired
- 1995-10-23 DK DK95934738T patent/DK0788480T3/da active
- 1995-10-23 PT PT95934738T patent/PT788480E/pt unknown
- 1995-10-23 MX MX9703024A patent/MX9703024A/es unknown
- 1995-10-23 ES ES95934738T patent/ES2202375T3/es not_active Expired - Lifetime
- 1995-10-23 AT AT95934738T patent/ATE245629T1/de active
- 1995-10-23 EP EP95934738A patent/EP0788480B1/en not_active Expired - Lifetime
- 1995-10-23 JP JP51373896A patent/JP3911545B2/ja not_active Expired - Lifetime
- 1995-10-23 DE DE69531356T patent/DE69531356T2/de not_active Expired - Lifetime
-
1997
- 1997-04-22 FI FI971711A patent/FI117438B/sv not_active IP Right Cessation
- 1997-04-24 NO NO971903A patent/NO309266B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE245629T1 (de) | 2003-08-15 |
| AU3704895A (en) | 1996-05-15 |
| ES2202375T3 (es) | 2004-04-01 |
| JP3911545B2 (ja) | 2007-05-09 |
| NO971903D0 (no) | 1997-04-24 |
| DK0788480T3 (da) | 2003-09-29 |
| MX9703024A (es) | 1997-10-31 |
| PL183210B1 (pl) | 2002-06-28 |
| WO1996012699A1 (en) | 1996-05-02 |
| JPH10507464A (ja) | 1998-07-21 |
| CA2200355A1 (en) | 1996-05-02 |
| FI971711A0 (sv) | 1997-04-22 |
| HU227420B1 (en) | 2011-05-30 |
| DE69531356T2 (de) | 2004-05-27 |
| CA2200355C (en) | 2007-03-06 |
| EP0788480B1 (en) | 2003-07-23 |
| PT788480E (pt) | 2003-12-31 |
| FI117438B (sv) | 2006-10-13 |
| HUT77631A (hu) | 1998-06-29 |
| AU698637B2 (en) | 1998-11-05 |
| DE69531356D1 (de) | 2003-08-28 |
| PL319829A1 (en) | 1997-09-01 |
| FI971711A (sv) | 1997-04-22 |
| NO971903L (no) | 1997-04-24 |
| US5994548A (en) | 1999-11-30 |
| EP0788480A1 (en) | 1997-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO309266B1 (no) | Fremgangsmåte for fremstilling av optisk anriket bupivacain | |
| WO2007038277A2 (en) | Resolution of alpha-(phenoxy) phenylacetic acid derivatives with naphthyl-alkylamines | |
| US20060135777A1 (en) | Method for the production of d-threo-2-phenyl-2-piperidine-2-yl acetates | |
| AU696875B2 (en) | New process for the preparation of ropivacaine hydrochloride monohydrate | |
| WO2002102777A2 (en) | NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERINDINYL]-1-HYDROXYBUTYL]-α, α-DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE | |
| JP2011012032A (ja) | 光学活性な３−アミノピペリジンの製造方法および製造の中間体 | |
| DK152752B (da) | Fremgangsmaade til fremstilling af l-sulpirid | |
| US7897777B2 (en) | Process of enantiomeric resolution of D,L-(±)-threo-methylphenidate | |
| KR100472609B1 (ko) | 레보부피바카인과그의유사체의결정화벙법 | |
| CN111302996A (zh) | 一种高手性纯度的富马酸氯马斯汀的制备方法 | |
| US20200131126A1 (en) | Process for the Separation of Optical Isomers of Racemic 3-Alkylpiperidine-Carboxylic Acid Ethyl Esters | |
| JP4000113B2 (ja) | （３ｓ）−３−メトキシカルボニル−４−フェニル酪酸金属塩およびその使用方法 | |
| EP1341762A1 (en) | Process for resolving racemic mixtures of piperidine derivatives | |
| WO2021166934A1 (ja) | ピロリジン化合物の製造方法 | |
| US20040039206A1 (en) | Process for resolving racemic mixtures of piperidine derivatives | |
| CN117510398A (zh) | 一种高光学纯度(3r,4r)/(3s,4s)-n-boc-4-氨基-3-羟基哌啶的制备方法 | |
| WO2000039090A1 (en) | Process for the preparation of paroxetine acetate and analogues thereof | |
| JPH0940621A (ja) | 光学活性インダニルメチルアミン誘導体及びその製造法 | |
| EP1140910A1 (en) | Process for the preparation of an acetate salt of paroxetine or paroxetine analogues | |
| EP1140911A1 (en) | Process for the preparation of an acetate salt of paroxetine or paroxetine analogues | |
| JPH0687828A (ja) | 環化反応を用いるジフルオロメチル化合物の合成 | |
| WO2000039123A1 (en) | Process for the preparation of an acetate salt of paroxetine or paroxetine analogues |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |